AEVANOVA NEWSAEVANOVA VESTI
Signal,
not noise.Signal,
bez šuma.
Material developments in peptide regulation, human research, clinical trials and analytical testing—reported from primary sources and separated from the evidence library.Važni događaji u regulativi peptida, istraživanjima na ljudima, kliničkim studijama i analitičkom testiranju—prikazani iz primarnih izvora i odvojeni od biblioteke dokaza.
FDA advisory committee reviews seven peptide-related substances for the 503A Bulks ListSavetodavni odbor FDA razmatrao sedam supstanci povezanih sa peptidima za 503A listu
BPC-157, KPV, TB-500 and MOTS-c were among the bulk drug substances discussed. The meeting was a 503A compounding-list review—not FDA approval of these substances as medicines.BPC-157, KPV, TB-500 i MOTS-c bili su među razmatranim aktivnim supstancama. Sastanak je bio procena za 503A listu za izradu lekova, a ne odobrenje FDA za ove supstance kao lekove.
Read the source-led briefPročitaj pregled zasnovan na izvorimaLilly discloses Phase III topline results from TRIUMPH-2 and TRIUMPH-3Lilly objavio preliminarne rezultate faze III iz TRIUMPH-2 i TRIUMPH-3
The two placebo-controlled studies add late-stage evidence in defined obesity populations, but detailed peer-reviewed reports were still pending at the time of disclosure.Dve placebom kontrolisane studije dodaju kasne kliničke dokaze u definisanim populacijama sa gojaznošću, ali su detaljni recenzirani izveštaji u trenutku objave još bili na čekanju.
Open briefOtvori pregled Peer-reviewed Phase III evidenceRecenzirani dokazi faze IIIFirst peer-reviewed Phase III retatrutide trial publishedObjavljena prva recenzirana studija faze III retatrutida
TRANSCEND-T2D-1 studied retatrutide monotherapy in 537 adults with type 2 diabetes inadequately controlled by diet and exercise.TRANSCEND-T2D-1 je proučavao monoterapiju retatrutidom kod 537 odraslih sa dijabetesom tipa 2 koji nije bio adekvatno kontrolisan ishranom i fizičkom aktivnošću.
Open briefOtvori pregledNews is not a clinical claim.Vest nije klinička tvrdnja.
A regulatory meeting, trial announcement, lawsuit or investment can be important without changing the established evidence for a compound. Every brief labels the source type and unresolved questions.Regulatorni sastanak, najava studije, sudski postupak ili investicija mogu biti važni bez promene utvrđenih dokaza za jedinjenje. Svaki pregled označava vrstu izvora i nerešena pitanja.